Detalles de la búsqueda
1.
Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial.
Lancet Oncol
; 23(3): 362-373, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-35131040
2.
Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.
N Engl J Med
; 378(15): 1408-1418, 2018 Apr 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-29420164
3.
Apalutamide plus Androgen Deprivation Therapy for Metastatic Castration-Sensitive Prostate Cancer: Analysis of Pain and Fatigue in the Phase 3 TITAN Study.
J Urol
; 206(4): 914-923, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34039013
4.
Apalutamide for metastatic, castration-sensitive prostate cancer in the Japanese population: A subgroup analysis of the randomized, double-blind, placebo-controlled phase 3 TITAN study.
Int J Urol
; 28(3): 280-287, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33295007
5.
Understanding symptomatic experience, impact, and emotional response in recently diagnosed metastatic castration-resistant prostate cancer: a qualitative study.
Support Care Cancer
; 28(7): 3093-3101, 2020 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-31659445
6.
Skin rash following Administration of Apalutamide in Japanese patients with Advanced Prostate Cancer: an integrated analysis of the phase 3 SPARTAN and TITAN studies and a phase 1 open-label study.
BMC Urol
; 20(1): 139, 2020 Sep 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-32878613
7.
Correction to: Skin rash following Administration of Apalutamide in Japanese patients with Advanced Prostate Cancer: an integrated analysis of the phase 3 SPARTAN and TITAN studies and a phase 1 open-label study.
BMC Urol
; 20(1): 166, 2020 Oct 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-33092574
8.
Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study.
Lancet Oncol
; 20(11): 1518-1530, 2019 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31578173
9.
Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial.
Lancet Oncol
; 19(10): 1404-1416, 2018 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-30213449
10.
11.
Health-related quality of life in GALAHAD: A multicenter, open-label, phase 2 study of niraparib for patients with metastatic castration-resistant prostate cancer and DNA-repair gene defects.
J Manag Care Spec Pharm
; 29(7): 758-768, 2023 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-37404070
12.
Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer.
J Clin Oncol
; 41(18): 3339-3351, 2023 06 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-36952634
13.
Efficacy and safety exposure-response relationships of apalutamide in patients with metastatic castration-sensitive prostate cancer: results from the phase 3 TITAN study.
Cancer Chemother Pharmacol
; 89(5): 629-641, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35366072
14.
Randomized, Open-Label Phase 2 Study of Apalutamide plus Androgen Deprivation Therapy versus Apalutamide Monotherapy versus Androgen Deprivation Monotherapy in Patients with Biochemically Recurrent Prostate Cancer.
Prostate Cancer
; 2022: 5454727, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36212187
15.
Deep Prostate-specific Antigen Response following Addition of Apalutamide to Ongoing Androgen Deprivation Therapy and Long-term Clinical Benefit in SPARTAN.
Eur Urol
; 81(2): 184-192, 2022 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-34916086
16.
Blood Biomarker Landscape in Patients with High-risk Nonmetastatic Castration-Resistant Prostate Cancer Treated with Apalutamide and Androgen-Deprivation Therapy as They Progress to Metastatic Disease.
Clin Cancer Res
; 27(16): 4539-4548, 2021 08 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-34112710
17.
Apalutamide and Overall Survival in Prostate Cancer.
Eur Urol
; 79(1): 150-158, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32907777
18.
Pharmacokinetic Drug-Drug Interaction of Apalutamide, Part 2: Investigating Interaction Potential Using a Physiologically Based Pharmacokinetic Model.
Clin Pharmacokinet
; 59(9): 1149-1160, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32338346
19.
Efficacy and safety of apalutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a subgroup analysis of a randomized, double-blind, placebo-controlled, Phase-3 study.
Prostate Int
; 8(4): 190-197, 2020 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-33425798
20.
Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer.
Clin Cancer Res
; 25(24): 7448-7454, 2019 12 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-31511295
Resultados
1 -
20
de 20
1
Próxima >
>>